Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin

MLA

Lucio Catalano, et al. “Thalidomide-Dexamethasone as up-Front Therapy for Patients with Newly Diagnosed Multiple Myeloma: Thrombophilic Alterations, Thrombotic Complications, and Thromboprophylaxis with Low-Dose Warfarin.” European Journal of Haematology, vol. 84, May 2010, pp. 484–92. EBSCOhost, https://doi.org/10.1111/j.1600-0609.2010.01434.x.

APA

Lucio Catalano, Michele Cavo, Patrizia Tosi, Francesca Patriarca, Lelia Valdrè, Cristina Legnani, Michela Cini, Elena Zamagni, Alessandro Gozzetti, Paola Tacchetti, Gualtiero Palareti, & Luciano Masini. (2010). Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin. European Journal of Haematology, 84, 484–492. https://doi.org/10.1111/j.1600-0609.2010.01434.x

Chicago

Lucio Catalano, Michele Cavo, Patrizia Tosi, Francesca Patriarca, Lelia Valdrè, Cristina Legnani, Michela Cini, et al. 2010. “Thalidomide-Dexamethasone as up-Front Therapy for Patients with Newly Diagnosed Multiple Myeloma: Thrombophilic Alterations, Thrombotic Complications, and Thromboprophylaxis with Low-Dose Warfarin.” European Journal of Haematology 84 (May): 484–92. doi:10.1111/j.1600-0609.2010.01434.x.